{"nctId":"NCT00191152","briefTitle":"A Phase III Trial For Patients With Metastatic Breast Cancer","startDateStruct":{"date":"2002-02"},"conditions":["Breast Cancer","Breast Neoplasms","Cancer of the Breast"],"count":475,"armGroups":[{"label":"Gemcitabine + Docetaxel","type":"EXPERIMENTAL","interventionNames":["Drug: gemcitabine","Drug: docetaxel"]},{"label":"Capecitabine + Docetaxel","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: docetaxel","Drug: capecitabine"]}],"interventions":[{"name":"gemcitabine","otherNames":["LY188011","Gemzar"]},{"name":"docetaxel","otherNames":[]},{"name":"capecitabine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologic or cytologic confirmation of breast cancer with locally advanced and/or metastatic disease\n* Patients may have received prior neo-adjuvant or adjuvant taxane regimen as long as it has been greater than or equal to 6 months since completion of the regimen\n* Patients may have had 0-1, but no more than one prior course of chemotherapy for metastatic disease\n* Patients must have either measurable or non-measurable (evaluable) disease\n* Prior radiation therapy allowed of less than 25% of the bone marrow\n\nExclusion Criteria:\n\n* Second primary malignancy (except in situ carcinoma of the cervix or adequately treated nonmelanomatous carcinoma of the skin or other malignancy treated at least 5 years previously with no evidence of recurrence)\n* Parenchymal or leptomeningeal brain metastases\n* Peripheral neuropathy greater than or equal to grade 2\n* Prior treatment with gemcitabine and capecitabine will not be allowed. Prior treatment with a taxane in the metastatic setting will not be allowed. Prior taxane therapy in the neo-adjuvant or adjuvant setting is allowed if completion of therapy greater than or equal to 6 months prior to enrollment.\n* Active cardiac disease not controlled by therapy and/or myocardial infarction within the preceding 6 months.\n* Concomitant Herceptin is not allowed","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Time to Disease Progression (Crossover Treatment)","description":"For crossover treatment, time to disease progression (TTDP) was defined as the number of months between the first dose date of crossover treatment and the date of disease progression or the date of death due to disease under study, whichever came first. TTDP for crossover treatment only applied to those participants who crossed over from initial treatment to crossover treatment. TTDP censored at earliest of: 1)date of death not due to disease; or 2)date of last contact for participants alive without disease progression; or 3)start date of other anti-tumor therapy due to progression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.51","spread":null},{"groupId":"OG001","value":"2.34","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (Initial Treatment)","description":"For initial treatment, progression-free survival (PFS) was defined as the number of months between the date of randomization and the date of first documented disease progression or the date of death due to any cause, whichever came first. Time to PFS was censored at the earliest of: 1) date of last contact for participants alive without disease progression; or 2) start date of other anti-tumor therapy for progression; or 3) first dose date of crossover treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.01","spread":null},{"groupId":"OG001","value":"8.88","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (Crossover Treatment)","description":"For crossover treatment, progression-free survival (PFS) was defined as the number of months between first dose date of crossover treatment and date of documented disease progression or date of death due to any cause, whichever came first. PFS for crossover treatment only applied to those participants who crossed over from initial treatment to crossover treatment. PFS was censored at the earliest of: 1) date of last contact for participants alive without disease progression; or 2) start date of other anti-tumor therapy for participants with documented disease progression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.51","spread":null},{"groupId":"OG001","value":"2.34","spread":null}]}]}]},{"type":"PRIMARY","title":"Time to Disease Progression (Initial Treatment)","description":"Time to disease progression (TTDP) at initial treatment was defined as the number of months between date of randomization and the date of first documented disease progression or the date of death due to disease under study, whichever came first. TTDP censored at earliest of: 1) date of death not due to disease; or 2) date of last contact for participants alive without disease progression; or 3) start date of other anti-tumor therapy; or 4) first dose date of crossover treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.28","spread":null},{"groupId":"OG001","value":"8.88","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (Initial Treatment)","description":"Among tumor responders, duration of tumor response was measured from the date of response (complete response \\[CR\\] or partial response \\[PR\\] until the first date of documented progression or death from any cause. Duration of response was censored at the earliest of: 1) date of last contact for participants alive without disease progression (DP); or 2) start date of other anti-tumor therapy for DP; or 3) dose date of crossover treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.11","spread":null},{"groupId":"OG001","value":"10.39","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (Crossover Treatment)","description":"At crossover treatment, duration of response was measured from the time criteria were met for complete response (CR) or partial response (PR), until first date that recurrent or progressive disease was objectively documented or date of death due to any cause, whichever came first. This definition only applied to those who crossed over \\& achieved CR or PR in crossover treatment. Duration of response censored at earliest of: 1) date of last contact for those alive without disease progression; or 2) start date of other anti-tumor therapy for documented disease progression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.89","spread":null},{"groupId":"OG001","value":"42.50","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival time was defined as the number of months between the date of randomization and the date of death due to any cause. The overall survival time was censored at the date of last contact for participants who were still alive.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.99","spread":null},{"groupId":"OG001","value":"23.29","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Overall Response (Initial Treatment)","description":"Best overall response was the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response was assessed using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that did not meet above criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Overall Response (Crossover Treatment)","description":"Best overall response was the best response recorded from the start of treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response assessed using RECIST criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that did not meet above criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Summary of Changes in Karnofsky Performance Status (KPS) by Treatment (Initial Treatment)","description":"KPS ranges from 0 to 100, subdivided into three categories: incapacitated (0-40), self-care (50-70), and normal activity (80-100).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.85","spread":"8.159"},{"groupId":"OG001","value":"90.09","spread":"8.335"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.30","spread":"9.259"},{"groupId":"OG001","value":"-3.27","spread":"9.118"}]}]}]},{"type":"SECONDARY","title":"Summary of Changes in Karnofsky Performance Status (KPS) by Treatment (Crossover Treatment)","description":"KPS ranges from 0 to 100, subdivided into three categories: incapacitated (0-40), self-care (50-70), and normal activity (80-100).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.09","spread":"7.174"},{"groupId":"OG001","value":"87.94","spread":"9.360"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.30","spread":"7.839"},{"groupId":"OG001","value":"-1.27","spread":"9.068"}]}]}]},{"type":"SECONDARY","title":"Summary of Changes in Rotterdam Symptom Checklist (RSCL) by Treatment (Initial Treatment)","description":"RSCL includes 4 scales to assess quality of life (QOL) endpoints: 1) a 23-item physical distress level with scale score ranges from 23 to 92 \\[low score represents better QOL\\] 2)a 7-item psychological distress level with scale score ranges from 7 to 28\\[low score represents better QOL\\] 3)8-item activity level with scale score ranges from 8 to 32 \\[high score represents better QOL\\]; 1-item overall valuation of life with score range from 1 to 7 \\[low score represents better QOL\\].","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.09","spread":"25.103"},{"groupId":"OG001","value":"72.32","spread":"23.693"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.42","spread":"27.093"},{"groupId":"OG001","value":"-2.68","spread":"26.685"}]}]}]},{"type":"SECONDARY","title":"Summary of Changes in Rotterdam Symptom Checklist by Treatment (Crossover Treatment)","description":"RSCL includes 4 scales to assess quality of life (QOL) endpoints: 1) a 23-item physical distress level with scale score ranges from 23 to 92 \\[low score represents better QOL\\] 2)a 7-item psychological distress level with scale score ranges from 7 to 28\\[low score represents better QOL\\] 3)8-item activity level with scale score ranges from 8 to 32 \\[high score represents better QOL\\]; 1-item overall valuation of life with score range from 1 to 7 \\[low score represents better QOL\\].","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.00","spread":"20.876"},{"groupId":"OG001","value":"76.39","spread":"17.663"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.78","spread":"21.029"},{"groupId":"OG001","value":"-0.69","spread":"27.133"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":72,"n":237},"commonTop":["Neutropenia","Fatigue","Nausea","Diarrhoea","Alopecia"]}}}